Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H6N4S |
| Molecular Weight | 166.204 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CSC1=NC=NC2=C1NC=N2
InChI
InChIKey=UIJIQXGRFSPYQW-UHFFFAOYSA-N
InChI=1S/C6H6N4S/c1-11-6-4-5(8-2-7-4)9-3-10-6/h2-3H,1H3,(H,7,8,9,10)
| Molecular Formula | C6H6N4S |
| Molecular Weight | 166.204 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. | 2010-12 |
|
| Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. | 2010-11-20 |
|
| A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. | 2010-11 |
|
| Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise. | 2010-06-01 |
|
| How should thiopurine treatment be monitored?--methodological aspects. | 2010-06 |
|
| Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. | 2010-02 |
|
| Patent watch. Drug metabolite claims are patentable. | 2009-11 |
|
| [Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites]. | 2009-02 |
|
| Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. | 2008-12 |
|
| Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. | 2008-12 |
|
| Stability of thiopurine metabolites: a potential analytical bias. | 2008-01 |
|
| Optimizing drug therapy in inflammatory bowel disease. | 2007-12 |
|
| 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. | 2007-07 |
|
| Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. | 2006-10 |
|
| Molecular mechanisms underlying the enhanced sensitivity of thiopurine-resistant T-lymphoblastic cell lines to methyl mercaptopurineriboside. | 2006-09-28 |
|
| Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center. | 2006-09 |
|
| [HPLC determination and diversity analysis of thiopurine methyltransferase activity in human and pig]. | 2006-05 |
|
| Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. | 2005-11 |
|
| Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. | 2005-08 |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005-06 |
|
| Determination of mercaptopurine and its four metabolites by large-volume sample stacking with polarity switching in capillary electrophoresis. | 2005-06 |
|
| Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. | 2004-11 |
|
| Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. | 2004-11 |
|
| Improved HPLC methodology for monitoring thiopurine metabolites in patients on thiopurine therapy. | 2004-09 |
|
| Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. | 2004-08 |
|
| Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. | 2004-01 |
|
| Real-time RT-PCR methodology for quantification of thiopurine methyltransferase gene expression. | 2003-07 |
|
| Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. | 2003-04-19 |
|
| Measurement of thiopurine S-methyltransferase activity in human blood samples based on high-performance liquid chromatography: reference values in erythrocytes from children. | 2003-01 |
|
| Determination of thiopurine S-methyltransferase phenotype using thin-layer chromatography and quantitative scanning. | 2002-04 |
|
| Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. | 2001-11 |
|
| Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. | 2001-10 |
|
| Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. | 2001-08-01 |
|
| Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. | 2001-06-05 |
|
| Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. | 2001-01 |
|
| Purine analogs as potential anticytomegalovirus agents. | 1969-09 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:40:26 GMT 2025
by
admin
on
Mon Mar 31 18:40:26 GMT 2025
|
| Record UNII |
6V404DV25O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5778
Created by
admin on Mon Mar 31 18:40:26 GMT 2025 , Edited by admin on Mon Mar 31 18:40:26 GMT 2025
|
PRIMARY | |||
|
28279
Created by
admin on Mon Mar 31 18:40:26 GMT 2025 , Edited by admin on Mon Mar 31 18:40:26 GMT 2025
|
PRIMARY | |||
|
6V404DV25O
Created by
admin on Mon Mar 31 18:40:26 GMT 2025 , Edited by admin on Mon Mar 31 18:40:26 GMT 2025
|
PRIMARY | |||
|
SUB181031
Created by
admin on Mon Mar 31 18:40:26 GMT 2025 , Edited by admin on Mon Mar 31 18:40:26 GMT 2025
|
PRIMARY | |||
|
200-057-3
Created by
admin on Mon Mar 31 18:40:26 GMT 2025 , Edited by admin on Mon Mar 31 18:40:26 GMT 2025
|
PRIMARY | |||
|
100000166797
Created by
admin on Mon Mar 31 18:40:26 GMT 2025 , Edited by admin on Mon Mar 31 18:40:26 GMT 2025
|
PRIMARY | |||
|
20105
Created by
admin on Mon Mar 31 18:40:26 GMT 2025 , Edited by admin on Mon Mar 31 18:40:26 GMT 2025
|
PRIMARY | |||
|
DTXSID50901654
Created by
admin on Mon Mar 31 18:40:26 GMT 2025 , Edited by admin on Mon Mar 31 18:40:26 GMT 2025
|
PRIMARY | |||
|
50-66-8
Created by
admin on Mon Mar 31 18:40:26 GMT 2025 , Edited by admin on Mon Mar 31 18:40:26 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE INACTIVE |
|
